Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | HRH2 | P25021 | 2/20 | 0.49 |
| ▸ | HRH1 | P35367 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13528714 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP2C19NPC1RAB9ATMEM97 | |
| SCHEMBL13528044 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP2C19NPC1RAB9ATMEM97 | |
| SCHEMBL13528054 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP2C19NPC1RAB9ATMEM97 | |
| SCHEMBL13528719 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP2C19NPC1RAB9ATMEM97 | |
| Hydrochloric Acid SCHEMBL28356355 | 0.94 | SMN1; SMN2 (0.60) | SMN1; SMN2CYP2C19NPC1RAB9ATMEM97 | |
| Hydrochloric Acid SCHEMBL28356358 | 0.94 | SMN1; SMN2 (0.60) | SMN1; SMN2CYP2C19NPC1RAB9ATMEM97 | |
| SCHEMBL2744456 | 0.88 | SMN1; SMN2 (0.64) | SMN1; SMN2CYP2C19NPC1RAB9ATMEM97 | |
| SCHEMBL14528537 | 0.86 | SMN1; SMN2 (0.64) | SMN1; SMN2CYP2C19NPC1RAB9ATMEM97 | |
| SCHEMBL14528428 | 0.86 | SMN1; SMN2 (0.64) | SMN1; SMN2CYP2C19NPC1RAB9ATMEM97 | |
| SCHEMBL13547179 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016289-A1 | Compounds Useful as Antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016289-A1 | Compounds Useful as Antagonists of CCR2 | CCR2, CCR1, CXCR3 | SMN1; SMN2 3730/4885CYP2C19 2350/4885NPC1 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.